The inhibition of MARK2 suppresses cisplatin resistance of osteosarcoma stem cells by regulating DNA damage and repair.

DNA-PKcs MARK2 PI3K/Akt/mTOR osteosarcoma stem cells

Journal

Journal of bone oncology
ISSN: 2212-1366
Titre abrégé: J Bone Oncol
Pays: Netherlands
ID NLM: 101610292

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 11 09 2019
revised: 01 04 2020
accepted: 01 04 2020
entrez: 6 5 2020
pubmed: 6 5 2020
medline: 6 5 2020
Statut: epublish

Résumé

This study aims to explore the role of MARK2 in chemotherapeutic resistance and potential mechanism within cisplatin resistance models of CD133 CD133 Compared with CD133 Our data suggested that MARK2 was related to cisplatin resistance in CD133

Identifiants

pubmed: 32368441
doi: 10.1016/j.jbo.2020.100290
pii: S2212-1374(20)30045-2
pii: 100290
pmc: PMC7184251
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100290

Informations de copyright

© 2020 Published by Elsevier GmbH.

Déclaration de conflit d'intérêts

None.

Références

Pathology. 2014 Feb;46(2):95-104
pubmed: 24378391
Pharmacol Ther. 2014 May;142(2):164-75
pubmed: 24333502
Cancer Treat Rev. 2006 Oct;32(6):423-36
pubmed: 16860938
Acta Biochim Biophys Sin (Shanghai). 2018 Jun 1;50(6):567-578
pubmed: 29718150
Life Sci. 2018 Mar 1;196:56-62
pubmed: 29355544
Biosci Rep. 2018 Dec 14;38(6):
pubmed: 30442873
Am J Cancer Res. 2015 Apr 15;5(5):1649-64
pubmed: 26175935
Oncol Rep. 2016 Oct;36(4):1973-80
pubmed: 27499034
Br J Cancer. 2010 Jan 5;102(1):206-12
pubmed: 19997106
Mol Med Rep. 2013 Feb;7(2):577-84
pubmed: 23242469
Cell. 1997 Apr 18;89(2):297-308
pubmed: 9108484
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5680-5
pubmed: 17372192
Tumour Biol. 2015 Dec;36(12):9365-72
pubmed: 26108997
PLoS One. 2008;3(10):e3469
pubmed: 18941626
Cancer Res. 2006 Mar 15;66(6):3126-36
pubmed: 16540663
Oncol Rep. 2014 Jun;31(6):2720-6
pubmed: 24788927
J Biol Chem. 2012 Mar 9;287(11):8174-86
pubmed: 22238344
Adv Ther. 2017 Jul;34(7):1556-1571
pubmed: 28547734
Front Oncol. 2014 Apr 14;4:64
pubmed: 24782981
Int J Oncol. 2017 Jan;50(1):93-100
pubmed: 27878245
PLoS One. 2014 Jun 03;9(6):e98549
pubmed: 24893164
Trends Biochem Sci. 2009 Jul;34(7):332-42
pubmed: 19559622
Biochem Pharmacol. 2010 Jul 15;80(2):262-76
pubmed: 20361941
Int J Cancer. 2015 Nov 1;137(9):2072-82
pubmed: 25907283

Auteurs

Liang Xu (L)

Department of Orthopaedics, Qilu Hospital of Shandong University, 107 Wenhuaxi Rd, Lixia District, Jinan 250012, Shandong, China.
Department of Orthopaedics, Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan 250012, Shandong, China.
Department of Orthopaedics, Shandong Provincial Chest Hospital, Jinan 250013, Shandong, China.

Zhengkao Sun (Z)

Department of Orthopaedics, Qilu Hospital of Shandong University (Qingdao), 758 Hefei Rd, North District, Qingdao 266035, Shandong, China.

Xianfu Wei (X)

Department of Orthopaedics, Qilu Hospital of Shandong University, 107 Wenhuaxi Rd, Lixia District, Jinan 250012, Shandong, China.

Hongdong Tan (H)

Department of Orthopaedics, Shandong Provincial Chest Hospital, Jinan 250013, Shandong, China.

Peng Kong (P)

Department of Orthopaedics, Shandong Traditional Chinese Medicine Hospital, Jinan 250014, Shandong, China.

Zhenfeng Li (Z)

Department of Orthopaedics, Qilu Hospital of Shandong University, 107 Wenhuaxi Rd, Lixia District, Jinan 250012, Shandong, China.

Qiang Yang (Q)

Department of Orthopaedics, Qilu Hospital of Shandong University, 107 Wenhuaxi Rd, Lixia District, Jinan 250012, Shandong, China.

E'nuo Dai (E)

Department of Orthopaedics, Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan 250012, Shandong, China.

Jianmin Li (J)

Department of Orthopaedics, Qilu Hospital of Shandong University, 107 Wenhuaxi Rd, Lixia District, Jinan 250012, Shandong, China.

Classifications MeSH